SCHEMBL7607178

SCHEMBL7607178

CC(C)(O)c1cccc2c1c(OCc1ccccc1)c(N(C=O)c1cccnc1)n2Cc1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.36
HDAC1 Q13547 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
TSHR P16473 2/20 0.34
USP2 O75604 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 2/20 0.34
CYP2D6 P10635 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC8 Q9BY41 1/20 0.33
HIF1A Q16665 1/20 0.33
LMNA P02545 2/20 0.33
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
PLA2G2A P14555 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7607138 0.84 HDAC1 (0.37) PKMHDAC1HDAC6SMN1; SMN2ALDH1A1
SCHEMBL7606207 0.84 HDAC1 (0.39) PKMHDAC1HDAC6SMN1; SMN2ALDH1A1
SCHEMBL7606176 0.84 HDAC6 (0.44) PKMHDAC1HDAC6SMN1; SMN2ALDH1A1
SCHEMBL7555714 0.82 HDAC6 (0.45) HDAC1HDAC6SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL7606062 0.80 HDAC6 (0.45) PKMHDAC1HDAC6SMN1; SMN2ALDH1A1
SCHEMBL7551884 0.79 HDAC6 (0.44) HDAC1HDAC6SMN1; SMN2ALDH1A1MAPK1
SCHEMBL7607184 0.79 LRRK2 (0.49) HDAC1HDAC6MEN1KMT2A
SCHEMBL7608458 0.78 HDAC1 (0.40) PKMHDAC1HDAC6SMN1; SMN2ALDH1A1
SCHEMBL7612615 0.78 MAPT (0.41) PKMHDAC1HDAC6ALDH1A1CYP1A2
SCHEMBL7611332 0.77 HDAC6 (0.44) HDAC1HDAC6SMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436965-B1 INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2002-08-20 US claimed
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US claimed
US-6436965-B1 INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2002-08-20 US disclosed
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment PDE3A, PDE3B, PDE4A PKM 734/4885HDAC1 45/4885HDAC6 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.